Myopia ProgressionMoMUS-DIMSNCT07679477
Management of Myopia in University Students With DIMS-TED Spectacle Lenses
A study testing DIMS TED spectacle lenses and Single vision spectacle lenses in people with Myopia Progression, run by University of Bradford at 2 sites in United Kingdom.
Trial summary
The purpose of the study is to quantify the effectiveness of Hoya MiyoSmart IQ (DIMS-TED) spectacle lenses in slowing the rate of myopia progression in university students. Read more about this study
- Who is it for?
- Ages 18 to 23 years
- Conditions the study is for
- Myopia Progression
- What is being tested?
- DIMS TED spectacle lenses and Single vision spectacle lenses
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 1 Oct 2025to 1 Oct 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 23 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Myopic students studying at university
- Aged 18-23 years at the start of the study
- Show evidence of axial length growth of at least 0.06mm prior to entry into Stage 2 of the study.
- Have read the patient information sheet and be happy to sign the consent forms
- Be willing to adhere to the visit schedule and wearing times described in the protocol
- Agree to accept either the control or test lenses as assigned by the randomisation
- Have BCVA of +0.10 LogMAR or better in each eye
Who cannot join
- Previous myopia control use (optical or pharmacological)
- Amblyopia
- Myopic Rx up to -10D
- Astigmatism up to 4D
- Anisometropia <1.75D
- Binocular Vision anomalies (such as tropia)
- Taking medications that affect pupil size or accommodation
- A known allergy to tropicamide
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites
University of Bradford
Bradford, West Yorkshire, BD7 1NP
University of Huddersfield
Huddersfield
About this study
Official title: Management of Myopia in University Students Using Defocus Incorporated Multiple Segment (DIMS) Spectacle Lenses.
The purpose of the study is to quantify the effectiveness of Hoya MiyoSmart IQ (DIMS-TED) spectacle lenses in slowing the rate of myopia progression in university students.
Read the detailed description
MiyoSmart spectacle lenses have been shown to be a safe and effective way of managing myopia progression in children aged 8-12 years. However, myopic progression is not limited to children of this age group and there is evidence that progression also occurs in university students. The researchers are therefore investigating the effectiveness of this intervention in a group of UK-based University students.
- Conditions
- Myopia Progression
- Being tested
- DIMS TED spectacle lenses, Single vision spectacle lenses
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DIMS TED spectacle lensesDevice
Spectacle lenses for myopia management
Single vision spectacle lensesDevice
Single vision spectacle lenses as control
| Study group | Role | What they receive |
|---|---|---|
| Experimental: DIMS TED scpectacle lenses | Experimental | Active Comparator: Single vision spectacle lenses Receives: Device: DIMS TED spectacle lenses |
| Active Comparator: Single vision spectacle lenses | Active comparator | Active Comparator: Single vision spectacle lenses Receives: Device: Single vision spectacle lenses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Axial length
Change in axial length relative to baseline
Measured: 24 months
Cycloplegic SER
Change in spherical equivalent cycloplegic autorefraction relative to baseline
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study start1 Oct 2025
- Primary completion1 Oct 2029 (estimated)
- Study completion1 Oct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Myopia ProgressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Bradford
- Sponsor type
- University, hospital or other
- Collaborators
- Hoya Vision Care, University of Huddersfield
- Responsible party
- Sponsor
- Investigators
- Neema Ghorbani-Mojarrad, PhD, Principal investigator, University of BradfordKathryn Webber, MOptom, Principal investigator, University of BradfordSophie Coverdale, PhD, Principal investigator, University of BradfordNiall Hynes, PhD, Principal investigator, University of HuddersfieldCheryl Hill, Principal investigator, University of Bradford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07679477
- Sponsor's protocol ID
- E1305
- Acronym
- MoMUS-DIMS
- Status last verified
- Jun 2026
- First submitted
- 25 Jun 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, Vlasak N, To CH. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023 Apr 4;13(1):5475. doi: 10.1038/s41598-023-32700-7.
PubMed 37015996Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368. doi: 10.1136/bjophthalmol-2018-313739. Epub 2019 May 29.
PubMed 31142465Bullimore MA, Lee SS, Schmid KL, Rozema JJ, Leveziel N, Mallen EAH, Jacobsen N, Iribarren R, Verkicharla PK, Polling JR, Chamberlain P. IMI-Onset and Progression of Myopia in Young Adults. Invest Ophthalmol Vis Sci. 2023 May 1;64(6):2. doi: 10.1167/iovs.64.6.2.
PubMed 37126362Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A, Buckhurst H, Collins M, Fujikado T, Hiraoka T, Hirota M, Jones D, Logan NS, Lundstrom L, Torii H, Read SA, Naidoo K. IMI - Clinical Myopia Control Trials and Instrumentation Report. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M132-M160. doi: 10.1167/iovs.18-25955.
PubMed 30817830
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Management of Myopia in University Students Using Defocus Incorporated Multiple Segment (DIMS) Spectacle Lenses.
- ClinicalTrials.gov ID
- NCT07679477
- Acronym / sponsor ID
- MoMUS-DIMS / E1305
- Conditions
- Myopia Progression
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- University of BradfordUniversity, hospital or other
- Collaborators
- Hoya Vision Care, University of Huddersfield
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 1 Oct 2029 (estimated)
- Study completion
- 1 Oct 2029 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to quantify the effectiveness of Hoya MiyoSmart IQ (DIMS-TED) spectacle lenses in slowing the rate of myopia progression in university students.
Detailed description
MiyoSmart spectacle lenses have been shown to be a safe and effective way of managing myopia progression in children aged 8-12 years. However, myopic progression is not limited to children of this age group and there is evidence that progression also occurs in university students. The researchers are therefore investigating the effectiveness of this intervention in a group of UK-based University students.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental: DIMS TED scpectacle lenses | Experimental | Device: DIMS TED spectacle lensesActive Comparator: Single vision spectacle lenses |
| Active Comparator: Single vision spectacle lenses | Active comparator | Device: Single vision spectacle lensesActive Comparator: Single vision spectacle lenses |
Who may qualify
- Ages
- 18 to 23 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Myopic students studying at university
- Aged 18-23 years at the start of the study
- Show evidence of axial length growth of at least 0.06mm prior to entry into Stage 2 of the study.
- Have read the patient information sheet and be happy to sign the consent forms
- Be willing to adhere to the visit schedule and wearing times described in the protocol
Key exclusion criteria (8 listed)
- Previous myopia control use (optical or pharmacological)
- Amblyopia
- Myopic Rx up to -10D
- Astigmatism up to 4D
- Anisometropia <1.75D
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DIMS TED spectacle lensesSpectacle lenses for myopia management | Device | Experimental: DIMS TED scpectacle lenses |
| Single vision spectacle lensesSingle vision spectacle lenses as control | Device | Active Comparator: Single vision spectacle lenses |
Primary outcome
Axial length
Time frame: 24 months
Change in axial length relative to baseline
Cycloplegic SER
Time frame: 24 months
Change in spherical equivalent cycloplegic autorefraction relative to baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Background: PubMed 37015996Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, Vlasak N, To CH. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023 Apr 4;13(1):5475. doi: 10.1038/s41598-023-32700-7.
- Background: PubMed 31142465Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368. doi: 10.1136/bjophthalmol-2018-313739. Epub 2019 May 29.
- Background: PubMed 37126362Bullimore MA, Lee SS, Schmid KL, Rozema JJ, Leveziel N, Mallen EAH, Jacobsen N, Iribarren R, Verkicharla PK, Polling JR, Chamberlain P. IMI-Onset and Progression of Myopia in Young Adults. Invest Ophthalmol Vis Sci. 2023 May 1;64(6):2. doi: 10.1167/iovs.64.6.2.
- Background: PubMed 30817830Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A, Buckhurst H, Collins M, Fujikado T, Hiraoka T, Hirota M, Jones D, Logan NS, Lundstrom L, Torii H, Read SA, Naidoo K. IMI - Clinical Myopia Control Trials and Instrumentation Report. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M132-M160. doi: 10.1167/iovs.18-25955.
- Individual participant dataSharing planned: Undecided
Related trials for Myopia Progression
Not yet recruiting
BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
Myopia, Myopia Progressing
Recruiting
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
Myopia, Myopia Progression
Recruiting
Children's Viewing Behavior
Myopia, Myopia Progression
Not yet recruiting
Comparing Myopia Control Spectacle Lenses and Standard Single Vision Spectacle Lenses in Children With Myopia
Myopia, Myopia Progression
Active, not recruitingPhase 3
The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children
Myopia Progression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Neema Ghorbani-Mojarrad, PhD principal investigator
University of Bradford
Kathryn Webber, MOptom principal investigator
University of Bradford
Sophie Coverdale, PhD principal investigator
University of Bradford
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DIMS TED spectacle lenses and Single vision spectacle lenses in people with Myopia Progression, run by University of Bradford at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Axial length (time frame: 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07679477, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.